Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction
- Author(s)
- Bostel, T; Nikolaidou, E; Wollschläger, D; Mayer, A; Kaufmann, J; Hopprich, A; Rühle, A; Grosu, AL; Debus, J; Fottner, C; Moehler, M; Grimminger, P; Schmidberger, H; Nicolay, NH;
- Details
- Publication Year 2024-03-04,Volume 19,Issue #1,Page 28
- Journal Title
- Radiation Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND: To assess the tolerability and oncological results of chemoradiation in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction. METHODS: This multi-center retrospective analysis included 86 elderly patients (≥ 65 years) with esophageal or gastroesophageal junction adenocarcinoma (median age 73 years; range 65-92 years) treated with definitive or neoadjuvant (chemo)radiotherapy. The treatment was performed at 3 large comprehensive cancer centers in Germany from 2006 to 2020. Locoregional control (LRC), progression-free survival (PFS), distant metastasis-free survival (DMFS), overall survival (OS), and treatment-associated toxicities according to CTCAE criteria v5.0 were analyzed, and parameters potentially relevant to patient outcomes were evaluated. RESULTS: Thirty-three patients (38%) were treated with neoadjuvant chemoradiation followed by surgery, while the remaining patients received definitive (chemo)radiation. The delivery of radiotherapy without dose reduction was possible in 80 patients (93%). In 66 patients (77%), concomitant chemotherapy was initially prescribed; however, during the course of therapy, 48% of patients (n = 32) required chemotherapy de-escalation due to treatment-related toxicities and comorbidities. Twenty-nine patients (34%) experienced higher-grade acute toxicities and 14 patients (16%) higher-grade late toxicities. The 2-year LRC, DMFS, PFS, and OS amounted to 72%, 49%, 46%, and 52%, respectively. In multivariate analysis, neoadjuvant chemoradiation followed by surgery was shown to be associated with significantly better PFS (p = 0.006), DMFS (p = 0.006), and OS (p = 0.004) compared with all non-surgical treatments (pooled definitive radiotherapy and chemoradiation). No such advantage was seen over definitive chemoradiation. The majority of patients with neoadjuvant therapy received standard chemoradiotherapy without dose reduction (n = 24/33, 73%). In contrast, concurrent chemotherapy was only possible in 62% of patients undergoing definitive radiotherapy (n = 33/53), and most of these patients required dose-reduction or modification of chemotherapy (n = 23/33, 70%). CONCLUSIONS: In our analysis, omission of chemotherapy or adjustment of chemotherapy dose during definitive radiotherapy was necessary for the overwhelming majority of elderly esophageal cancer patients not eligible for surgery, and hence resulted in reduced PFS and OS. Therefore, optimization of non-surgical approaches and the identification of potential predictive factors for safe administration of concurrent chemotherapy in elderly patients with (gastro)esophageal adenocarcinoma is required.
- Publisher
- BioMed Central
- Keywords
- Aged; Humans; Retrospective Studies; Esophagogastric Junction; *Esophageal Neoplasms/therapy; *Adenocarcinoma/therapy; *Stomach Neoplasms; Aeg; Adenocarcinoma; Chemoradiation; Elderly patients; Esophageal cancer; Gastroesophageal Junction tumor; Radiotherapy
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1186/s13014-024-02414-9
- Open Access at Publisher's Site
https://doi.org/10.1186/s13014-024-02414-9- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-28 06:48:09
Last Modified: 2024-03-28 06:51:46